BIOVIE INC

BIVINASDAQ

🏆 #4900 by market capUS Equity

$1.54▼ $0.00 (−0.32%)

After hours · at close

🔔

Track BIVI

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 0.3%

7d▼ 5.5%

14d▼ 10.5%

30d▼ 29.0%

ytd▲ 33.3%

1y▼ 17.6%

🏦Market Cap

$12M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Fair

Trading Snapshot

Day Range: $1.52 – $1.57
52-Week Range: $0.82 – $3.79
Volume: $3.78B
Avg Volume: $4.81B
Shares Outstanding: 7.5M
Next Earnings: Nov 29, 2026

Fundamentals Snapshot

Annual Revenue: $829,400
Last Q Revenue: $194,613
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-3.15
Dividend Yield: —
Dilution (1yr): −4.8%

Why Investors Own BIVI

✓High-growth profile — revenue up -3.1% YoY with expanding US Equity exposure.
✓Healthy economics — 60% gross margin and 12% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

BIOVIE INC

BIVI

Financial Trends

Revenue

$0▲ +0.0% YoY

Operating Income

−$23M▲ +25.4% YoY

Free Cash Flow

−$19.0B▲ +99897.9% YoY

Shares Outstanding

7.5M▼ −4.8% YoY

Net Cash

$9M▼ −$12M YoY

StockOtter · stockotter.space

About BIOVIE INC

BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease. Further preclinical investigations are underway for NE3107, exploring its potential applications in treating multiple myeloma and prostate cancer. Established in 2013, the company adopted its current name, BioVie Inc., in July 2016, having previously operated as NanoAntibiotics, Inc. Its corporate headquarters are situated in Carson City, Nevada.

🦦